CryoCor European Recall Drops Sales As Firm Submits Atrial Flutter PMA
This article was originally published in The Gray Sheet
CryoCor does not believe a European recall of its Model 1200 cryoablation device will hamper efforts to secure PMA approval for the unit's successor, CryoBlator, in the U.S
You may also be interested in...
CryoCor will use approximately 35% of the $31.7 mil. it expects to net from an initial public offering to continue product development and complete a Phase II clinical trial of cryoablation to treat atrial flutter
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.